Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-interventional, Multi-center, Observational Post Authorization Safety Study of Patients With Relapse/Refractory Multiple Myeloma Treated With Lenalidomide in Turkey

NCT02387879 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT02387879
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02387879 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-interventional, Multi-center, Observational Post Authorization Safety Study of Patients With Relapse/Refractory Multiple Myeloma Treated With Lenalidomide in Turkey
Lead sponsor
Celgene
Phase
Observational
Overall status
Unknown status
Start date
December 25, 2013
Completion date
December 31, 2022
Enrollment
500 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma